Summary of Significant Accounting Policies - Summary of Disaggregation of Revenue by Product Platform/Type (Detail) - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2017
Segment Reporting Information [Line Items]
Revenue	$ 201,014	$ 213,571	$ 200,771
Revenue, % change	(6.00%)	6.00%
Diagnostics [Member]
Segment Reporting Information [Line Items]
Revenue	$ 136,682	$ 150,454	143,521
Revenue, % change	(9.00%)	5.00%
Diagnostics [Member] | Molecular Assays [Member]
Segment Reporting Information [Line Items]
Revenue	$ 26,231	$ 33,709	33,712
Revenue, % change	(22.00%)
Diagnostics [Member] | Immunoassays & Blood Chemistry Assays [Member]
Segment Reporting Information [Line Items]
Revenue	$ 110,451	$ 116,745	109,809
Revenue, % change	(5.00%)	6.00%
Life Science [Member]
Segment Reporting Information [Line Items]
Revenue	$ 64,332	$ 63,117	57,250
Revenue, % change	2.00%	10.00%
Life Science [Member] | Molecular Reagents [Member]
Segment Reporting Information [Line Items]
Revenue	$ 23,261	$ 24,533	21,966
Revenue, % change	(5.00%)	12.00%
Life Science [Member] | Immunological Reagents [Member]
Segment Reporting Information [Line Items]
Revenue	$ 41,071	$ 38,584	$ 35,284
Revenue, % change	6.00%	9.00%